Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
Metrics to compare | LIPUM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIPUMPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.0x | −11.3x | −0.5x | |
PEG Ratio | −0.18 | −0.21 | 0.00 | |
Price/Book | 108.7x | 5.9x | 2.6x | |
Price / LTM Sales | - | 68.9x | 3.3x | |
Upside (Analyst Target) | 56.9% | 102.3% | 43.4% | |
Fair Value Upside | Unlock | 18.3% | 7.1% | Unlock |